AU2001266787A1 - Nucleic acids, proteins, and antibodies - Google Patents

Nucleic acids, proteins, and antibodies

Info

Publication number
AU2001266787A1
AU2001266787A1 AU2001266787A AU6678701A AU2001266787A1 AU 2001266787 A1 AU2001266787 A1 AU 2001266787A1 AU 2001266787 A AU2001266787 A AU 2001266787A AU 6678701 A AU6678701 A AU 6678701A AU 2001266787 A1 AU2001266787 A1 AU 2001266787A1
Authority
AU
Australia
Prior art keywords
antibodies
proteins
nucleic acids
nucleic
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266787A
Inventor
Charles E. Birse
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2001266787A1 publication Critical patent/AU2001266787A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
AU2001266787A 2000-06-07 2001-06-07 Nucleic acids, proteins, and antibodies Abandoned AU2001266787A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20946700P 2000-06-07 2000-06-07
US60209467 2000-06-07
PCT/US2001/018569 WO2002000677A1 (en) 2000-06-07 2001-06-07 Nucleic acids, proteins, and antibodies

Publications (1)

Publication Number Publication Date
AU2001266787A1 true AU2001266787A1 (en) 2002-01-08

Family

ID=22778864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266787A Abandoned AU2001266787A1 (en) 2000-06-07 2001-06-07 Nucleic acids, proteins, and antibodies

Country Status (3)

Country Link
US (1) US20040005579A1 (en)
AU (1) AU2001266787A1 (en)
WO (1) WO2002000677A1 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507937A (en) 1997-01-14 2001-06-19 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Tumor necrosis factor receptor 6α and tumor necrosis factor receptor 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2004043361A2 (en) * 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR100399982B1 (en) * 2000-06-16 2003-11-13 학교법인고려중앙학원 Novel mouse CIA protein and CIA gene having anti-apoptotic activity as a selective inhibitor of CAD interacting with ASK1 and use thereof
CN1329031A (en) * 2000-06-19 2002-01-02 上海博德基因开发有限公司 A novel polypeptide-human RNA conjugated protein 19 and polynucleotide for coding this polypeptide
AU2001277109A1 (en) * 2000-07-21 2002-02-05 Millennium Pharmaceuticals, Inc. 56939, a human acyl-coa thioesterase family member and uses thereof
WO2002036808A2 (en) * 2000-11-03 2002-05-10 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7153678B2 (en) 2000-12-20 2006-12-26 Bristol-Myers Squibb Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
MXPA03009510A (en) * 2001-04-17 2005-04-29 Univ Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions.
CN100447154C (en) * 2001-05-15 2008-12-31 费因斯坦医学研究学院 Use of HMG fragments as anti-inflammatory agents
CA2448253A1 (en) * 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20030120040A1 (en) * 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
WO2003010198A1 (en) * 2001-07-26 2003-02-06 Kenton Srl Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US7306919B1 (en) * 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
US7504222B2 (en) * 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003104428A2 (en) * 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets
JPWO2003070947A1 (en) * 2002-02-19 2005-06-09 株式会社 ビーエフ研究所 Apoptosis-promoting substance and inhibitory substance interacting with CGI-94 and screening method thereof
CA2478850C (en) 2002-03-13 2018-02-27 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
WO2003093826A2 (en) * 2002-04-29 2003-11-13 Clinigenetics Assays for identifying cholesterol - lowering molecules
US20040121362A1 (en) 2002-06-20 2004-06-24 Whitney Gena S. Identification and modulation of a G-protein coupled receptor (GPCR), RAI-3, associated with chronic obstructive pulmonary disease (COPD) and NF-kappaB and E-selectin regulation
WO2004005463A2 (en) * 2002-07-03 2004-01-15 Aventis Pasteur Inc. Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
WO2004005501A1 (en) * 2002-07-08 2004-01-15 Bayer Healthcare Ag Regulation of human casein kinase i epsilon
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US7678889B2 (en) 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
WO2004024952A1 (en) * 2002-08-30 2004-03-25 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
JP4988201B2 (en) 2002-10-16 2012-08-01 ユーロ−セルティーク エス．エイ． Antibody binding to cell-bound CA125 / O772P and method of use thereof
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20070154886A1 (en) 2002-12-06 2007-07-05 Macina Roberto A Composition, splice variants and methods relating to ovarian specific genes and proteins
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP4568716B2 (en) 2003-02-20 2010-10-27 ジェノミック ヘルス， インコーポレイテッド Use of intron RNA to measure gene expression
SI1606409T1 (en) * 2003-03-19 2011-01-31 Biogen Idec Inc Nogo receptor binding protein
EP3470535B1 (en) 2003-06-24 2020-04-01 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005014818A1 (en) 2003-08-08 2005-02-17 Perseus Proteomics Inc. Gene overexpressed in cancer
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005034732A2 (en) * 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
CA2445743A1 (en) * 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
KR20070000438A (en) 2003-12-23 2007-01-02 게노믹 헬쓰, 인코포레이티드 Universal amplification of fragmented rna
US7569662B2 (en) 2004-01-27 2009-08-04 Compugen Ltd Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
US7667001B1 (en) 2004-01-27 2010-02-23 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
JP5813908B2 (en) 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド Gene expression markers to predict response to chemotherapeutic agents
EP2070546A1 (en) 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
ES2395094T3 (en) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Treatment of conditions that involve demyelination
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
ES2384107T3 (en) 2004-11-05 2012-06-29 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and treatment response prediction
CA2593034A1 (en) * 2004-12-09 2006-06-15 The Brigham And Women's Hospital, Inc. Compositions and methods based upon the kinase haspin
WO2006108095A2 (en) * 2005-04-06 2006-10-12 The University Of Maryland, Baltimore Serum biomarker for disease and methods of using same
WO2006121869A2 (en) * 2005-05-05 2006-11-16 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating mood and anxiety disorders
NZ564762A (en) * 2005-05-26 2011-10-28 Univ Johns Hopkins Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2007005733A2 (en) * 2005-07-01 2007-01-11 Cornell Research Foundation, Inc. Novel peptides promoting neurite outgrowth
BRPI0613387A2 (en) 2005-07-08 2011-01-11 Biogen Idec Inc isolated antibody or antigen binding fragment thereof and its use, isolated polynucleotide, composition, vector, host cell, anti-sp35 antibody and method for producing the same, isolated polypeptide, in vitro method for reducing inhibition of axonal growth and in vitro method for inhibiting cone collapse growth
ATE509096T1 (en) 2006-06-16 2011-05-15 Onco Therapy Science Inc SPARC-DERIVED CANCER REJECTION ANTIGEN PEPTIDE AND PHARMACEUTICAL CONTAINING SAME
PE20081456A1 (en) 2006-10-06 2008-11-27 Takeda Pharmaceutical MONOCLONAL ANTIBODY AGAINST NECTIN 2
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
JP5144742B2 (en) * 2007-03-29 2013-02-13 フジレビオ ダイアグノスティックス インコーポレイテッド Use of HE4 for breast cancer assessment
US20100272635A1 (en) * 2007-06-15 2010-10-28 Rodems Kelline M Methods and compositions for diagnosis and/or prognosis in ovarian cancer and lung cancer
AU2008289148A1 (en) * 2007-08-16 2009-02-26 Aventis Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
JP5754046B2 (en) * 2007-11-08 2015-07-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Use of a LINGO-4 antagonist in the treatment of conditions involving demyelination
EP2237792B1 (en) 2007-12-26 2017-05-24 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
WO2009144704A2 (en) * 2008-04-15 2009-12-03 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS FOR INHIBITING NRF2
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
US20110286924A1 (en) * 2008-12-09 2011-11-24 Alethia Biotherapeutics Inc Novel human endogenous retroviral erv3 variant and uses thereof in the diagnosing ovarian cancer
AU2010224031B2 (en) * 2009-03-11 2013-05-02 Abraxis Bioscience, Llc SPARC angiogenic domain and methods of use
JP5802195B2 (en) 2009-04-27 2015-10-28 オタワ ホスピタル リサーチ インスティチュート Compositions and methods for modulating stem cells and uses thereof
EP2437768B1 (en) 2009-06-04 2016-08-10 The University of North Carolina At Chapel Hill Compounds and methods for treating bone disorders and controlling weight
WO2013040341A2 (en) 2011-09-16 2013-03-21 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
BR112014006321A2 (en) * 2011-09-16 2017-04-11 Fate Therapeutics Inc wnt compositions and therapeutic uses of such composition
WO2013155567A1 (en) * 2012-04-20 2013-10-24 Mat Malta Advanced Technologies Limited Sex determination genes
EA030716B1 (en) 2012-05-14 2018-09-28 Байоджен Ма Инк. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2015000014A1 (en) * 2013-07-01 2015-01-08 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
HUE056760T2 (en) 2013-07-11 2022-03-28 Modernatx Inc Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015129790A1 (en) * 2014-02-26 2015-09-03 株式会社バイオイミュランス Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US10525101B2 (en) 2015-10-23 2020-01-07 Oregon Health & Science University Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
US11639371B2 (en) * 2016-02-17 2023-05-02 The Chinese University Of Hong Kong Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
DE102018200518B4 (en) * 2018-01-15 2023-09-14 Robert Bosch Gmbh Microfluidic device and method for its operation
CN112557347B (en) * 2020-11-12 2023-10-24 渤海大学 Preparation and detection method of chyle particle migration model in mucus layer
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity

Also Published As

Publication number Publication date
WO2002000677A8 (en) 2002-07-04
WO2002000677A1 (en) 2002-01-03
US20040005579A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
AU2001241415A1 (en) Nucleic acids, proteins, and antibodies
AU2001266787A1 (en) Nucleic acids, proteins, and antibodies
AU2001237947A1 (en) Nucleic acids, proteins, and antibodies
AU2001237953A1 (en) Nucleic acids, proteins, and antibodies
AU2001239726A1 (en) Nucleic acids, proteins, and antibodies
AU2001239728A1 (en) Nucleic acids, proteins, and antibodies
AU2001241403A1 (en) Nucleic acids, proteins, and antibodies
AU2001237948A1 (en) Nucleic acids, proteins, and antibodies
AU2001241411A1 (en) Nucleic acids, proteins, and antibodies
AU2001241419A1 (en) Nucleic acids, proteins, and antibodies
AU2001230958A1 (en) Nucleic acids, proteins, and antibodies
AU2001236460A1 (en) Nucleic acids, proteins, and antibodies
AU2001236459A1 (en) Nucleic acids, proteins, and antibodies
AU2001243137A1 (en) Nucleic acids, proteins, and antibodies
AU2001247190A1 (en) Nucleic acids, proteins, and antibodies
AU2001237946A1 (en) Nucleic acids, proteins, and antibodies